TargetBeta
MC4R
melanocortin 4 receptor · Melanocortin receptors
4 programs in company-led studies act on MC4R, from 3 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| setmelanotiderule | Rhythm Pharmaceuticals | phase 4 | 223 running | – | ChEMBL |
| bremelanotiderule | Palatin Technologies | phase 4 | 81 running | – | ChEMBL |
| bivamelagonrule | Rhythm Pharmaceuticals | phase 2 | 32 running | – | NCIt |
| mifomelatiderule | Endevica Bio | phase 2 | 21 running | MC3R | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Obesity, 3 programs
- Sexual Infantilism, 2 programs
- Cachexia, 1 program
- Colorectal Neoplasms, 1 program
- Hypertriglyceridemia, 1 program
- Kidney Diseases, 1 program
- Overweight, 1 program
- Prader-Willi Syndrome, 1 program
- Sexual Dysfunctions, Psychological, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 13, 2027setmelanotide · Rhythm Pharmaceuticals · phase 4 · NCT06760546
- Oct 2027mifomelatide · Endevica Bio · phase 2 · NCT06937177
- Apr 15, 2028bivamelagon · Rhythm Pharmaceuticals · phase 2 · NCT07156578
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.